Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist
US10561704B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 8, 2014 |
| Grant date | Feb 18, 2020 |
| Priority date | — |
| Expiry date | Jul 8, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/36
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for treating neuropsychiatric disorders in vertebrates and humans. More specifically, the present invention provides for use of IRL-1620, an endothelin-B receptor agonist, in appropriate doses to be a neuroprotective and a neuroregenerative agent. Accordingly, in one aspect the disclosure provides a method of treating a neuropsychiatric disorder comprising administering to a patient in need thereof a therapeutically effective amount of an endothelin-B receptor agonist to treat the neuropsychiatric disorder. In some embodiments, the endothelin-B receptor agonist is co-administered with an additional agent to treat the neuropsychiatric disorder. In some embodiments, the additional agent is selected from the group consisting of an antidepressant, an anti-inflammatory agent, a CNS stimulant, a neuroleptic, and an anti-proliferative agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.